Does TALAZOPARIB Cause Interstitial lung disease? 5 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Interstitial lung disease have been filed in association with TALAZOPARIB (Talzenna). This represents 0.3% of all adverse event reports for TALAZOPARIB.
5
Reports of Interstitial lung disease with TALAZOPARIB
0.3%
of all TALAZOPARIB reports
0
Deaths
4
Hospitalizations
How Dangerous Is Interstitial lung disease From TALAZOPARIB?
Of the 5 reports, 4 (80.0%) required hospitalization.
Is Interstitial lung disease Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TALAZOPARIB. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does TALAZOPARIB Cause?
Anaemia (219)
Neoplasm progression (169)
Death (142)
Off label use (78)
Thrombocytopenia (78)
Fatigue (77)
Platelet count decreased (68)
Haemoglobin decreased (65)
Febrile neutropenia (60)
Pancytopenia (60)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which TALAZOPARIB Alternatives Have Lower Interstitial lung disease Risk?
TALAZOPARIB vs TALC
TALAZOPARIB vs TALIGLUCERASE ALFA
TALAZOPARIB vs TALIMOGENE LAHERPAREPVEC
TALAZOPARIB vs TALQUETAMAB
TALAZOPARIB vs TALQUETAMAB-TGVS